Back to journals
Academic JournalOpen Access

Brain Sciences

7 Papers Indexed in Blossom

Data updated

Research Footprint

Brain Sciences has 7 tracked papers indexed in Blossom (2018–2026) from 48 authors, most often covering Ketamine, Placebo and Psilocybin, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Substance Use Disorders (SUD).

Published Papers

Open Accessindividual

Effects of a Single Sub-Anesthetic Dose of Ketamine in Tobacco Use Disorder: An Active-Placebo, Randomized Crossover Study

This randomised crossover study (n=18) tested a single sub-anesthetic ketamine infusion against midazolam in adults with tobacco use disorder who were not trying to quit smoking. Ketamine was well tolerated but did not clearly reduce smoking, craving or withdrawal, although some participants reported stronger psychological effects and found abstaining easier afterwards.

Published
Journal
Brain Sciences
Authors
Luzum, N. R., McCall, M. H., Talley Boyd, C., Columbano, H., Ip, E., Saldana, S., Oliveto, A. H., Addicott, M.
Paywallmeta

Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials

This systematic review and meta-analysis found that psilocybin markedly reduces depressive symptom severity in patients with primary MDD or TRD, with both single‑dose and two‑dose regimens producing significant improvements. Two‑dose administration sometimes yielded more pronounced and longer‑lasting effects, but it remains unclear whether this reflects dosing or other confounding factors, so standardised head‑to‑head trials are needed.

Published
Journal
Brain Sciences
Authors
Salvetti, G., Saccenti, D., Moro, A. S., Lamanna, J., Ferro, M.
Open Accessindividual

The Patient's Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression

This open-label prospective study (n=25) evaluated esketamine nasal spray (ESK-NS) treatment for treatment-resistant depression (TRD). Over three months, patients reported early and sustained improvements in depression, anhedonia, and suicidality, while clinicians detected improvements that varied at different time points.

Published
Journal
Brain Sciences
Authors
Pepe, M., Bartolucci, G., Marcelli, I., Pesaresi, F., Brugnami, A., Cas, R., Fischetti, A., Grisoni, F., Mazza, M., Camardese, G., Nicola, M. D., Sani, G.
Open Accessindividual

Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression

This case series (n=4) reflects on the use of ketamine (35mg/70kg, up to 8x) as an adjunct treatment for psychotic treatment-resistant depression (TRD). It finds that all participants were in remission after treatment and that suicidal ideation went down.

Published
Journal
Brain Sciences
Authors
Chmielewska, Z., Jakuszkowiak-Wojten, K., Wiglusz, M. S., Cubała, W. J., Galuszko-Wegielink, M.
Open Accessmeta

Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions

This review (2022) explores the current evidence and future directions for using ketamine to treat eating disorders (EDs). Potential mechanisms of action, the role of psychotherapy and limitations are discussed.

Published
Journal
Brain Sciences
Authors
Ragnhildstveit, A., Slayton, M., Jackson, L. K., Brendle, M., Ahuja, S., Holle, W., Moore, C., Sollars, K., Seli, P., Robison, R.
Open Accessmeta

Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature

This review (2021, s=30) investigates the use of ketamine for OCD, addiction (SUD), and eating disorders (ED) and finds that glutamatergic neurotransmission dysregulation underlies these domains. In this area, ketamine can be helpful.

Published
Journal
Brain Sciences
Authors
Martinotti, G., Pettorruso, M.

Quick Facts

Papers Indexed
7
h-Index
78
Open Access
Yes
Publisher
MDPI
Country
Switzerland
Website
Visit